Skip to main content
Clinical Trials/NCT06182683
NCT06182683RecruitingNot Applicable

Concurrent OPTIcal Coherence Tomography and frActional Flow REserve-guided Therapeutic Intervention in Patients With Coronary Artery Disease (OPTICARE-CAD)

Korea University Guro Hospital1 site in 1 country700 target enrollmentStarted: November 30, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
700
Locations
1
Primary Endpoint
Rate of target vessel failure (TVF)

Study Overview

Brief Summary

The present study is a prospective randomized clinical trial aimed to compare the therapeutic strategy of angiography-guided versus concurrent OCT/FFR-guided intervention in patients with coronary artery disease.

Detailed Description

Most previous clinical trials have assessed various interventional strategies guided by intravascular imaging (intravascular imaging-guided PCI), fractional flow reserve (FFR-guided PCI), or conventional angiography (angiography-guided PCI) to compare differences in treatment outcomes. Until now, it remains unclear whether optimizing procedures based on both intravascular imaging and fractional flow reserve indices would lead to improved treatment outcomes compared to PCI guided solely by conventional angiography. Moreover, there are no studies comparing a treatment strategy that combines optical coherence tomography (OCT) and FFR to angiography-guided procedures. Hence, this study aims to compare the clinical effectiveness and therapeutic impact of concurrent guidance using FFR and OCT in patients undergoing coronary artery stent implantation, as compared to procedures guided solely by conventional angiography.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Masking Description

No blinding process, open label design

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age greater than 19 years old
  • •Patients undergoing coronary stent implantation for stable angina or acute coronary syndrome
  • •Patients provided on informed consent

Exclusion Criteria

  • •Individuals with a history of increased bleeding tendencies or hematologic disorders
  • •Presented with refractory cardiogenic shock
  • •Individuals with a history of stent thrombosis
  • •Expected life expectancy of less than 1 year
  • •Left ventricular ejection fraction (LVEF) ≥ 20%
  • •Women who are breastfeeding, pregnant, or planning to become pregnant
  • •Deemed unsuitable for participation by the investigator
  • •Patients unwilling to participate in the clinical trial

Arms & Interventions

Angiography-guided PCI group

Active Comparator

This group of patients are intended to undergo PCI with conventional angiography-guidance. Procedural optimization determined by angiographic assessment.

Intervention: Coronary angiography (Diagnostic Test)

Concurrent OCT/FFR-guided PCI group

Experimental

This group of patients are intended to undergo PCI with concurrent OCT/FFR-guidance. Procedural optimization determined by OCT and FFR assessment.

Intervention: optical coherence tomography and fractional flow reserve (Diagnostic Test)

Concurrent OCT/FFR-guided PCI group

Experimental

This group of patients are intended to undergo PCI with concurrent OCT/FFR-guidance. Procedural optimization determined by OCT and FFR assessment.

Intervention: Coronary angiography (Diagnostic Test)

Outcomes

Primary Outcomes

Rate of target vessel failure (TVF)

Time Frame: 1-year

a composite endpoint of cardiac death, target vessel-related non-fatal myocardial infarction, clinically driven-target vessel revascularization

Secondary Outcomes

  • Rate of any myocardial infarction (MI)(1-year)
  • Rate of clinically-driven target vessel revascularization (TVR)(1-year)
  • Rate of all-cause mortality(1-year)
  • Rate of any revascularization(1-year)
  • Rate of stent thrombosis (acute, subacute, late, very late)(1-year)
  • Rate of BARC-defined bleeding(1-year)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Kang Dong Oh

Assistant Professor

Korea University Guro Hospital

Study Sites (1)

Loading locations...

Similar Trials